Search Bar & Filters
Found 29 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, and pharmacokinetics of SHR-4685 in adults with advanced solid tumors. This phase I study aims to determine the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of SHR-4685, helping to understand how the drug behaves in the body and its potential side effects. Participants will receive SHR-4685 in varying doses as part of a single treatment group. The study monitors participants for up to 24 months to assess adverse events, serious adverse events, and drug concentration levels in plasma. The treatment period includes regular assessments at predefined intervals to gather detailed pharmacokinetic data and observe tumor response measures. During the study, participants will undergo evaluations including tumor measurements based on RECIST 1.1 criteria, laboratory tests to monitor organ function and presence of antibodies against SHR-4685, and safety assessments to track side effects. Researchers will measure outcomes such as objective response rate, disease control rate, duration of response, and progression-free survival. Safety monitoring continues for 30 days after the last dose, and the total participation can last up to two years.
Actively Recruiting
Researchers are evaluating the effectiveness of N-acetylcysteine NAC in improving treatment outcomes for people with alcohol use disorder. This phase 4, double-blind, randomized, placebo-controlled trial aims to address the limited efficacy of current medications for alcohol dependence and explore personalized medicine strategies based on individual differences. The study is sponsored by the University of Sydney and involves 280 participants who have heavy drinking habits and a desire to reduce or stop drinking. Participants will be randomly assigned to receive either NAC at a dose of 2400 mg per day administered as 600 mg capsules taken twice twice daily for a total of 12 weeks along with standard medical management, or a matched placebo with the same schedule and standard care. The trial uses quadruple masking to keep participants, care providers, investigators, and outcome assessors unaware of group assignments. Treatment lasts for 12 weeks, followed by monitoring. During the study, participants will be assessed over 24 weeks for outcomes including the number of heavy drinking days, changes in liver function, and absence of heavy drinking days. Researchers will conduct interviews and monitor adherence, cognition, and safety. Participants must have stable housing and be able to consent and complete research interviews in English. Safety monitoring includes exclusion of unstable medical or psychiatric conditions and pregnancy screening. The total study duration includes the 12 weeks of treatment and follow-up assessments to measure drinking behavior and liver function.
Actively Recruiting
Researchers are evaluating DR-01, a non-fucosylated human immunoglobulin G1 monoclonal antibody, in adult patients with large granular lymphocytic leukemia or various cytotoxic lymphomas. This first-in-human, multicenter Phase 12 study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in these patient populations. The study is sponsored by Dren Bio and involves sequential dose escalation and expansion cohorts to find the optimal treatment regimen. Participants will receive DR-01 at different starting doses ranging from 0.3 mgkg to 10 mgkg, following one of three dosing schedules during the first month bi-weekly dosing, dosing on days 1, 8, 15, and 29, or dosing on days 1-5, 15, and 29. After the first month, dosing continues monthly with doses adjusted up to 10 mgkg for up to 25 cycles. Dose escalation and de-escalation cohorts are included, and optimized dosing regimens are evaluated separately for leukemia and lymphoma subjects in expansion phases. Throughout the study, participants will be monitored for adverse events, dose-limiting toxicities, and overall response rates using disease-specific criteria. Safety and pharmacological assessments will occur up to 25 months, with special focus on the first 28 days for dose-limiting toxicities and up to 6 months for dose optimization. Participants will undergo regular evaluations including clinical assessments and tissue biopsies when applicable. The study aims to determine the best dosage while closely monitoring safety and treatment effects over two years.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral nuvisertib TP-3654 in patients with intermediate or high-risk primary or secondary myelofibrosis. This Phase 12, multicenter, open-label trial includes patients who have previously been treated with JAK inhibitors or are ineligible for such treatments. The study aims to understand nuvisertibs effects in different patient groups based on prior treatment history and current medication use. Participants are assigned to one of three groups nuvisertib alone for those intolerant or resistant to JAK inhibitors nuvisertib added to stable doses of ruxolitinib for patients with lost or suboptimal response or nuvisertib combined with momelotinib for those previously treated with a JAK inhibitor other than momelotinib. Treatments are given orally, with dosing adjusted through dose escalation phases. The study monitors patients from initial treatment through ongoing assessment periods. Throughout the trial, participants undergo evaluations including spleen volume measurement by MRI or CT, symptom scoring using the Myelofibrosis Symptom Assessment Form, and monitoring for adverse events. Researchers track dose-limiting toxicities and treatment-emergent adverse events, as well as pharmacokinetic parameters like drug concentration and half-life. The study also assesses changes in symptoms and spleen size over time. Participation may last several months, with regular visits for assessments and safety monitoring until the studys completion.
Actively Recruiting
Researchers are evaluating the safety and changes in disease activity of different treatment combinations using mirvetuximab soravtansine with carboplatin, bevacizumab, or bevacizumab alone in adult women with ovarian cancer. This phase 2 study focuses on participants confirmed to have folate receptor alpha positive tumors through a specific assay. The purpose is to assess adverse events and treatment responses across multiple treatment groups. Participants will be assigned to one of three substudies, each with different treatment arms. Treatments involve intravenous infusions of mirvetuximab soravtansine combined with bevacizumab, carboplatin, or both, with dosing variations and sequences depending on the substudy. The study duration varies from approximately 31 to 40 months based on the treatment group and includes follow-up after initial combination therapies. During the study, participants will attend regular hospital or clinic visits for medical assessments including blood tests and scans. Researchers will monitor treatment-emergent adverse events, ocular adverse events, peripheral neuropathy, lung disease, and overall and progression-free survival using standardized criteria. The safety and effectiveness of the treatments will be tracked over the entire study period, which may require a higher treatment burden than standard care.
Actively Recruiting
Researchers are evaluating the safety and changes in disease activity of surzetoclax, an investigational oral drug, alone or combined with other treatments in adults with relapsed or refractory multiple myeloma MM, a disease where abnormal plasma cells grow in the bone marrow. This Phase 12 study is designed to find the best doses of surzetoclax in combination with other antimyeloma agents or alone, involving about 325 adult participants worldwide. The study includes multiple substudy phases to explore different drug combinations and dosing schedules for relapsedrefractory MM. Participants will receive surzetoclax with other drugs such as daratumumab given by injection, dexamethasone oral, pomalidomide oral, or etentamig intravenous infusion, depending on the substudy group. The study has dose escalation and optimization phases to determine the best doses of surzetoclax and other agents. Some participants will receive surzetoclax alone, while others receive it combined with other antimyeloma treatments. The total study duration is about 4.5 years. During the study, participants will attend regular visits at approved centers for medical assessments, blood tests, and monitoring of side effects. Researchers will track adverse events and measure disease activity changes. The main outcomes include dose-limiting toxicities and adverse events over up to 4.5 years. Secondary outcomes evaluate response rates, progression-free survival, duration of response, and overall survival. Participants will be closely monitored throughout the study period to assess treatment effects and safety.
Actively Recruiting
Researchers are evaluating elritercept compared with epoetin alfa to treat anemia in adults with lower-risk myelodysplastic syndromes LR-MDS who require regular red blood cell transfusions. The study focuses on how well elritercept reduces the need for transfusions, improves hemoglobin blood levels, and affects tiredness and quality of life. It also monitors the safety of elritercept and its impact on the disease in bone marrow and other body areas. Participants will be randomly assigned to receive either elritercept or epoetin alfa. Elritercept is given as a subcutaneous injection starting at 3.75 mgkg once every 4 weeks, with possible dose increases to 5.0 mgkg if needed. Epoetin alfa is given as a subcutaneous injection starting at 450 IUkg once weekly, with potential dose escalation up to 1050 IUkg maximum 80,000 IU. Treatment cycles last 28 days, and dosing continues throughout the study. During the study, participants will have regular assessments including blood tests to measure hemoglobin levels and transfusion requirements. Researchers will track fatigue and quality of life using specific questionnaires. Safety will be closely monitored, including side effects and changes in disease status. The main outcome is the proportion of participants who become independent of red blood cell transfusions for at least 12 consecutive weeks while having improved hemoglobin. The study may last up to approximately 5 years from the first dose to end of treatment.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of standard chemotherapy with or without the drug INCB161734 in people with metastatic pancreatic ductal adenocarcinoma PDAC that has a specific KRAS G12D mutation. This is a Phase 3 randomized, double-blind trial aiming to compare these treatments in patients who have not received prior systemic treatment for their metastatic cancer. Participants will receive either oral INCB161734 tablets or placebo tablets alongside chemotherapy chosen by the investigator, either mFOLFIRINOX or GemNabP, as per the study protocol. The study compares these two groups to assess outcomes such as survival and response to treatment. Treatment and observation will continue for up to approximately two to three years depending on the outcome being measured. During the trial, participants will undergo regular assessments including survival monitoring, tumor response evaluations by blinded independent central review and investigator assessments, and quality of life questionnaires. Researchers will also monitor adverse events and organ function. The study involves scheduled visits and tests over the course of treatment and follow-up lasting up to several years to understand long-term effects and treatment impact.
Actively Recruiting
Researchers are evaluating the effectiveness of glofitamab alone compared with the choice of either rituximab plus bendamustine or lenalidomide with rituximab in patients with relapsed or refractory mantle cell lymphoma. This Phase III study aims to determine which treatment better controls the disease in adults who have already received prior therapies, including a BTK inhibitor. The study involves random assignment to one of the treatment groups to compare outcomes over time. Participants assigned to the glofitamab group will receive two intravenous doses of obinutuzumab before starting intravenous glofitamab, given in 12 cycles of 21 days each. Those in the comparator group will receive either bendamustine plus rituximab for up to six 28-day cycles or rituximab plus oral lenalidomide daily for 21 days in 28-day cycles until the disease worsens. Tocilizumab may be given intravenously as needed to manage side effects related to immune response. During the study, participants will undergo regular assessments to monitor disease progression, response to treatment, physical functioning, fatigue, and lymphoma symptoms using questionnaires and clinical evaluations. Researchers will also measure drug levels and immune responses up to 24 months after randomization. Safety and effectiveness will be closely tracked, including survival and duration of response, to understand the benefits and risks of each treatment option.
Actively Recruiting
Researchers are evaluating whether a combination of elranatamab, daratumumab, and lenalidomide provides better clinical benefits compared to a combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in people newly diagnosed with multiple myeloma who cannot have a transplant. This phase 3 study includes two parts the first focuses on safety, tolerability, and dose finding for elranatamab combinations, while the second compares treatment effectiveness and progression outcomes between the two combination therapies. Participants receive different drug combinations depending on the study part and assigned group. Part 1 evaluates elranatamab combined with daratumumab and lenalidomide or elranatamab with lenalidomide alone, focusing on dose levels. Part 2 randomly assigns participants to receive either elranatamab with daratumumab and lenalidomide or the comparator regimen of daratumumab, bortezomib, lenalidomide, and dexamethasone. During the study, participants undergo regular assessments to monitor safety, treatment response, and disease progression, including measuring minimal residual disease negative complete response and progression-free survival. Researchers also track overall survival, adverse events, lab results, drug pharmacokinetics, and quality of life over an extended follow-up lasting up to approximately eight years after randomization.
1-10 of 29
1